leadf
logo-loader
viewTRACON Pharmaceuticals

TRACON Pharmaceuticals files pivotal ENVASARC protocol with FDA for its sarcoma treatment drug

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theur tells Proactive the biotech has filed the pivotal ENVASARC protocol with the FDA to study single-domain antibody envafolimab as a treatment for sarcoma.

Theur says its Investigational New Drug application cross-references the open envafolimab IND maintained by TRACON’s corporate partners 3D Medicines and Alphamab Oncology.

Quick facts: TRACON Pharmaceuticals

Price: 4.94 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $65.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

TRACON Pharmaceuticals approved by the FDA to begin sarcoma cancer therapy...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive the FDA has given the go-ahead for its human trial of envafolimab for sarcoma cancer. Theuer says it expects to start enrolling patients in the trial at 25 sites in the US in the fourth quarter of 2020.

on 08/18/2020

2 min read